North Macedonia's Rise as a European Medical Cannabis Supplier

August 29, 2026

Photo by Freek Wolsink via Pexels.

Drive an hour outside Skopje and you'll pass greenhouses that didn't exist a decade ago, growing a crop that would have gotten you arrested not long before. North Macedonia has quietly become one of Europe's more consequential medical cannabis suppliers, and the numbers from Germany prove it isn't just talk. The country now ranks fourth among Germany's cannabis import sources, trailing only Canada, Portugal and Denmark -- a remarkable position for a nation of roughly 1.8 million people with no history of large-scale pharmaceutical export industry before 2016.

The growth curve is the real headline. North Macedonian exports to Germany jumped from 2,666 kilograms in 2024 to 8,190 kilograms in 2025 -- roughly a threefold increase in a single year, and one that outpaced almost every other supplier country's growth rate. That kind of jump doesn't happen by accident; it reflects real cultivation capacity, real GMP-certified processing, and real contracts with German pharmacies and distributors.

But there's a less flattering story running underneath the export charts. A smuggling case involving more than 8,800 kilograms of dried flower -- diverted from a licensed grower and routed toward unauthorized sale rather than legitimate pharmaceutical export -- has exposed just how porous the country's licensing system can be. North Macedonia's rise is real. So are the cracks in the foundation supporting it, and neighboring countries weighing their own medical cannabis laws are watching both halves of that story just as closely.

How North Macedonia Built Its Legal Framework

North Macedonia moved early. On February 9, 2016, it legalized the cultivation, processing and manufacture of medical cannabis under amendments to its Law on Control of Narcotic Drugs and Psychotropic Substances, putting it well ahead of most of its Balkan neighbors and even some Western European countries in building out a formal regulatory regime for the plant. At the time, this made it one of the first comprehensive medical cannabis frameworks in the region, predating similar moves in Greece, Poland and the Czech Republic's expanded programs.

The regulatory structure splits oversight across three bodies, which was meant to create checks and balances but has also created some of the friction the industry deals with today. The Ministry of Health sets overall policy and issues cultivation and processing licenses. The Agency for Medicines and Medical Devices, commonly known by its Macedonian acronym MALMED (or AMMD), handles quality standards and pharmaceutical compliance. The Ministry of Interior manages security clearances and monitors the chain of custody, given that these are still classified narcotic substances under Macedonian law regardless of their medical end use.

Getting into this business requires clearing two separate technical hurdles. Cultivation licenses demand compliance with Good Agricultural and Collection Practice, or GACP, standards -- covering everything from seed sourcing to harvest handling to prevent contamination and ensure consistent cannabinoid content. Processing and manufacturing licenses require Good Manufacturing Practice, GMP, certification, the same pharmaceutical-grade standard used for conventional drug manufacturing in the EU. Companies need both, often through separate facilities and separate audits, before a gram of product can legally leave the country as a finished extract or oil.

One restriction has shaped the entire industry's structure: dried flower export remains prohibited. Only extracts and oil-based products can cross the border legally. A reform bill floated around 2019 and revisited in 2021 would have lifted that restriction and created an independent regulatory agency to replace the current three-way split, but it was shelved despite sustained lobbying from cultivators who argued flower exports would open a far larger and more lucrative European market.

The Germany Pipeline: A Threefold Jump

North Macedonia's cannabis exports to Germany surged from 2,666 kg in 2024 to 8,190 kg in 2025, more than tripling in a single year.

The trade data tells a story of genuinely fast growth. North Macedonia shipped 8,190 kilograms of cannabis product to Germany over the course of 2025, up from 2,666 kilograms in all of 2024. Even before the year closed, the trajectory was obvious: the first three quarters of 2025 alone totaled 5,765 kilograms, already a 116% increase over the entirety of the previous year's shipments. That's not incremental growth from an established exporter -- that's a supply chain scaling up in real time to meet demand it wasn't fully built for a few years earlier.

That volume is enough to put North Macedonia fourth on the list of countries supplying Germany's medical cannabis market, behind Canada, Portugal and Denmark -- three countries with far longer track records and, in Canada's case, a fully legalized adult-use industry to draw production capacity from. For a Balkan country to crack the top four against that competition says something about how quickly Macedonian producers have adapted to EU pharmaceutical standards.

Context matters here, though, because North Macedonia isn't just riding its own growth -- it's riding Germany's. Germany's total cannabis imports climbed to roughly 72 tonnes in 2024, then swelled to an estimated 201 tonnes in 2025, with projections pointing toward something near 250 tonnes in 2026. Germany's 2024 cannabis reforms, which loosened possession rules and expanded the framework for medical prescribing, have driven demand across every supplier country simultaneously, not just North Macedonia. The country is growing fast, but it's growing fast inside a market that's growing even faster.

Smaller volumes of Macedonian cannabis product also move to Poland, the Czech Republic, Israel, Australia and the UK, though none of those approach the scale of the German pipeline. Germany remains, by a wide margin, the market that determines whether a Macedonian cultivator's business plan works or doesn't.

Who's Actually Growing and Exporting

The licensing numbers only tell half the story if you stop at the headline figure. As of 2022, North Macedonia had issued 66 cultivation and production licences -- a number that looked, on paper, like a thriving young industry. But industry estimates put the number of companies actually exporting commercially at somewhere between 10 and 15. The gap between those two figures is the real story of how this industry actually functions.

What separates a paper licence holder from a working exporter usually comes down to money and technical capacity. Reaching EU-GMP certification isn't a formality -- it requires purpose-built cleanroom facilities, validated extraction processes, consistent batch testing, and the kind of quality management systems that cost real capital to install and maintain. Most smaller licence holders, often family operations or investors who got in early expecting a quick return, simply can't clear that bar. They hold a licence that permits them to grow, but not one that lets them sell into the pharmaceutical markets where the money actually is.

By 2025, roughly 100 companies held processing licenses in North Macedonia -- but the Ministry of Health itself has acknowledged that 35 of those licenses are no longer valid, whether through expiration, non-renewal, or revocation. That's more than a third of the nominal processing sector existing only on outdated paperwork.

The companies actually moving product to Germany and elsewhere are a much smaller, more identifiable group. Names like PharmaRolly, Green Medicals -- which operates in partnership with the German firm Cantourage -- IRDC, and PharmaCann/NYSK come up repeatedly in export records and industry reporting as the operators with functioning GMP facilities and standing contracts abroad. These handful of companies are effectively carrying the country's export reputation on their backs, while dozens of other licence holders remain either dormant, undercapitalized, or quietly out of compliance.

The upshot is that North Macedonia's cannabis licensing regime has vastly outpaced its population of companies actually capable of meeting pharmaceutical-grade export standards -- a mismatch that creates opportunity for legitimate growth, but also creates the kind of unused licences and idle inventory that can attract less legitimate interest.

The Alfapharm Case and the Grey Zones

Photo by Sasun Bughdaryan via Unsplash.

That less legitimate interest surfaced in a case that's become a cautionary reference point across the region. Skopje's Basic Criminal Court sentenced two men to three-and-a-half years and three years and eight months, respectively, for smuggling marijuana from North Macedonia into Serbia -- a scheme that hinged directly on the flower-export ban baked into Macedonian law.

The mechanics of the case were straightforward and, in retrospect, exploited an obvious weak point. A company called Alfapharm procured 8,832 kilograms of dried cannabis flower from CBD Med Plant, a licensed grower based in Strumica, in the country's southeast. Court records showed the flower had been contracted and financed well in advance -- not for legitimate processing into extract, which is the only legal export path for Macedonian flower, but for unauthorized sale, apparently routed toward Serbia and onward markets where dried flower commands a straightforward black-market price without the cost of GMP processing.

The scale of that single seizure -- more flower than North Macedonia's entire annual export volume to Germany at points during this same period -- pushed the case into a broader reckoning. Record seizures in early 2026 prompted Macedonian authorities to publicly commit to closing what officials themselves described as grey zones in the licensing system, acknowledging that the current structure leaves too much room for licensed growers to originate product that never reaches its declared destination.

The Alfapharm case wasn't an isolated compliance failure, either. Health Ministry data shows 14 separate firms have lost their permits for non-compliance in recent years, a figure distinct from the 35 invalidated processing licenses noted elsewhere in the system -- meaning enforcement action has touched both the cultivation and processing sides of the industry.

A May 2026 analysis from the Global Initiative Against Transnational Organized Crime went further, linking the case to what it characterized as weak safeguards against organized crime infiltrating the country's licensed cannabis supply chain -- a framing that's likely to shape how neighboring regulators approach their own licensing designs going forward.

Why the Region Is Watching Closely

Photo by jay stonne via Unsplash.

Albania and Bosnia and Herzegovina are both weighing medical cannabis legalization of their own, and both governments have been notably more cautious than North Macedonia was in 2016 -- a caution that traces directly back to watching Skopje's enforcement troubles play out in real time. Where North Macedonia moved fast and built its framework as an early mover, its neighbors now have a live case study of what can go wrong when licensing volume outpaces enforcement capacity, and they're designing around it rather than repeating it.

The flower-export ban sits at the center of the debate, and the Alfapharm case complicates the argument on both sides of it. The ban was written specifically to keep Macedonian product inside tightly controlled pharmaceutical supply chains, forcing every export through the extraction and GMP-processing bottleneck where it can be tracked and verified. What the Alfapharm case demonstrates is that the ban doesn't eliminate the underlying risk -- it just relocates it. Flower that can't legally leave the country as flower still finds a route out, just through diversion rather than declared export.

That's exactly the argument industry groups have been making in pushing to revive the shelved reform bill, which would create an independent regulatory agency and, more controversially, legalize flower export outright. Their case is that consolidating oversight under one dedicated agency, rather than splitting it across the Ministry of Health, MALMED and the Ministry of Interior, would actually reduce the kind of gaps that let a scheme like Alfapharm's operate for as long as it apparently did -- and that legal flower export would remove the incentive to smuggle it in the first place.

Whatever North Macedonia decides, the commercial pressure isn't going anywhere. Germany's demand curve, approaching a projected 250 tonnes in 2026, means the financial incentive to find workarounds around export restrictions will keep growing right alongside the legitimate market. Neighboring regulators know that, and it's shaping their caution as much as the smuggling case itself.

Strip away the smuggling headlines and North Macedonia has still built something genuinely substantial: a functioning pharmaceutical-grade cannabis export industry that didn't exist a decade ago, now supplying Europe's largest medical cannabis market at a scale that's climbing by the year. The Germany numbers aren't a projection or an aspiration -- they're shipped, received, and accounted for kilograms, and they've earned North Macedonia a spot ahead of every other country in the world except three.

But the licensing math is the part that should give regulators, and prospective investors, real pause. Sixty-six to a hundred licence holders, against a working export sector of maybe ten to fifteen companies, with 35 processing licenses and multiple cultivation permits already pulled for non-compliance -- that's not the profile of a mature industry. It's the profile of a system still in the process of sorting out which of its licensed participants are building real businesses and which ones were always going to be a liability.

How North Macedonia resolves that sorting process will probably decide which version of this story gets told in five years. Tighten enforcement, consolidate oversight, and the country plausibly becomes the template other Balkan nations point to when building their own programs. Leave the grey zones as they are, and the next Alfapharm-sized case won't read as an aberration -- it'll read as the predictable outcome of a licensing system that grew faster than its ability to police itself.